Ranbaxy: A Relook - Elliott Wave Analysis

In continuation with previous post titled "India Pharma Focus"  and the Ranbaxy Chart. I think we are more or less headed to for wave v lower on Ranbaxy with today's 7% move down. Let us see if the trendlines hold.



Here is the latest update on the wave count.

India Pharma Focus

I have no idea what our pharma companies do.. But, it seems many are about to lose their safe haven status soon. here is a look at Glenmark, Dr Reddy, Ranbaxy, Cipla and Aurobindo Pharma

1. Glenmark Pharma

2. Dr Reddy

3. Ranbaxy

4. CIPLA

5. AUROPHARMA

These studies are based on technical analysis and the author nor the webpage shall be responsible for the profits or losses. The author may or may not have personal holding. We are all students

Ranbaxy: Upside Potential (Inv HnS)

Inverted  HnS in Ranbaxy. Target of 520 possible with stoploss of 444. 

 

These studies are based on technical analysis and the author nor the webpage shall be responsible for the profits or losses. The author may or may not have personal holding.
We are all students